Good to see Permetrex delivery technology as part of this study:
'This ability to rapidly add new clinical programs which utilise synthetic cannabidiol and Permetrex™, bodes well for product development and partnering opportunities for the broader Botanix pipeline in psoriasis and other skin diseases. '
Also interesting to learn that:
'Before the recent approval of Crisaborole®, there had been no new drugs approved for atopic dermatitis for more than 15 years and based on successful Phase 3 studies, Pfizer acquired the company that developed Crisaborole® (Anacor Pharmaceuticals Inc.) for US$5.2 billion in May 2016.'
Ann: Botanix Commences BTX 1204 Dermatitis Patient Study, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
15.8¢ |
Change
-0.008(4.55%) |
Mkt cap ! $308.8M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.3¢ | 15.5¢ | $1.743M | 10.93M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 91 | 5764882 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 2429619 | 28 |
View Market Depth
| Last trade - 14.48pm 30/07/2025 (20 minute delay) ? |
| BOT (ASX) Chart |